FDA.reportPublic FDA data

lazertinib 240 MG (equivalent to lazertinib mesylate 281.58 MG) Oral Tablet

RxCUI
2691164
RxNorm name
lazertinib 240 MG (equivalent to lazertinib mesylate 281.58 MG) Oral Tablet
Display name
lazertinib 240 MG (equivalent to lazertinib mesylate 281.58 MG) Oral Tablet
Full name
lazertinib 240 MG (equivalent to lazertinib mesylate 281.58 MG) Oral Tablet
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:20

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
LAZCLUZELAZERTINIBJanssen Biotech, Inc.c417f9ee-2027-4ed5-92ad-3c19266de16c2026-05-05Warnings, Adverse reactionsExact identifier
rxcui: 2691164

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
c417f9ee-2027-4ed5-92ad-3c19266de16clazertinib 240 MG Oral Tablet [PSN] · lazertinib 240 MG Oral Tablet [SCD] · lazertinib 240 MG (equivalent to lazertinib mesylate 281.58 MG) Oral Tablet [SY]36These highlights do not include all the information needed to use LAZCLUZE safely and effectively. See full prescribing information for LAZCLUZE. LAZCLUZE ® (lazertinib) tablets, for oral use Initial U.S. Approval: 202420260505